Biogen’s (Nasdaq: BIIB) salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim findings from a Phase I study.
The investigational antisense oligonucleotide for spinal muscular atrophy (SMA) is being developed in collaboration with Ionis Pharmaceuticals (Nasdaq: IONS).
The once‑a‑year treatment demonstrated signs of substantial slowing of neurodegeneration, as measured by neurofilament light‑chain levels. Exploratory outcomes in treated children pointed to meaningful gains in motor function and acquisition of World Health Organization milestones over 12 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze